Willkie represented NextPharma in its agreement to purchase two production sites from Lonza Group AG, a listed Swiss multinational chemicals and biotechnology company.
On January 19, Willkie client NextPharma announced it had reached an agreement to purchase two production sites from Lonza Group AG, a listed Swiss multinational chemicals and biotechnology company, headquartered in Basel, with major facilities in Europe, North America and South Asia.
The sites produces liquid-filled hard capsules (including Licaps) and softgels (including for high potent and hormonal products) for the pharmaceutical and consumer health and nutrition markets. NextPharma offers CDMO services in oral and topical (including sterile ophthalmic) finished dosage forms.
With the acquisition, NextPharma plans to develop and broaden its technology offering into lipid based finished dosage forms (softgels and liquid-filled hard capsules), in addition to offering high potency capabilities and new chemical entity development services to customers.
The Willkie deal team was led by London partners David Arnold and Andrew Gray and included tax partner Jane Scobie and associates Meghal Mehta, Daniel Mulligan and Scott Wallace.